Test Research, Inc.

TWSE:3030 Voorraadrapport

Marktkapitalisatie: NT$33.5b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Test Research Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Test Research heeft een totaal eigen vermogen van NT$7.4B en een totale schuld van NT$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk NT$10.5B en NT$3.1B. De EBIT Test Research is NT$1.7B waardoor de rentedekking -132.6 is. Het heeft contanten en kortetermijnbeleggingen van NT$1.7B.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

NT$0

Schuld

Rente dekkingsratio-132.6x
ContantNT$1.68b
AandelenNT$7.35b
Totaal verplichtingenNT$3.12b
Totaal activaNT$10.47b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Test Research, Inc.'s (TWSE:3030) Popularity With Investors Under Threat As Stock Sinks 27%

Aug 05
Test Research, Inc.'s (TWSE:3030) Popularity With Investors Under Threat As Stock Sinks 27%

Test Research (TWSE:3030) May Have Issues Allocating Its Capital

Jul 11
Test Research (TWSE:3030) May Have Issues Allocating Its Capital

Test Research (TWSE:3030) Has Announced That Its Dividend Will Be Reduced To NT$3.30

Jun 01
Test Research (TWSE:3030) Has Announced That Its Dividend Will Be Reduced To NT$3.30

Optimistic Investors Push Test Research, Inc. (TWSE:3030) Shares Up 67% But Growth Is Lacking

May 31
Optimistic Investors Push Test Research, Inc. (TWSE:3030) Shares Up 67% But Growth Is Lacking

Test Research, Inc.'s (TWSE:3030) 25% Share Price Surge Not Quite Adding Up

Apr 15
Test Research, Inc.'s (TWSE:3030) 25% Share Price Surge Not Quite Adding Up

Is Test Research, Inc. (TPE:3030) A Smart Choice For Dividend Investors?

Mar 19
Is Test Research, Inc. (TPE:3030) A Smart Choice For Dividend Investors?

With EPS Growth And More, Test Research (TPE:3030) Is Interesting

Mar 01
With EPS Growth And More, Test Research (TPE:3030) Is Interesting

Should You Invest In Test Research (TPE:3030)?

Feb 11
Should You Invest In Test Research (TPE:3030)?

Test Research (TPE:3030) Has Compensated Shareholders With A Respectable 70% Return On Their Investment

Jan 24
Test Research (TPE:3030) Has Compensated Shareholders With A Respectable 70% Return On Their Investment

Is Test Research, Inc.'s (TPE:3030) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 05
Is Test Research, Inc.'s (TPE:3030) Latest Stock Performance Being Led By Its Strong Fundamentals?

Is Test Research, Inc. (TPE:3030) A Good Dividend Stock?

Dec 18
Is Test Research, Inc. (TPE:3030) A Good Dividend Stock?

Here's Why I Think Test Research (TPE:3030) Is An Interesting Stock

Nov 30
Here's Why I Think Test Research (TPE:3030) Is An Interesting Stock

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$6.3B ) 3030 } overtreffen de korte termijn passiva ( NT$2.8B ).

Langlopende schulden: De kortetermijnactiva 3030 ( NT$6.3B ) overtreffen de langetermijnschulden ( NT$271.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 3030 is schuldenvrij.

Schuld verminderen: 3030 heeft de afgelopen 5 jaar geen schulden gehad.

Schuldendekking: 3030 heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: 3030 heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Balans

Ontdek gezonde bedrijven

7D

1Y

7D

1Y

7D

1Y